Acumen Pharmaceuticals Inc (ABOS) Quote

Exactly, " some patients that have now been treated for 12 months already."

Sadly with management saying nothing will be reported publicly until the end of the trial, this stock will be manipulated.

Newmanhead....as noted earlier, at around a buck, what do you have to lose? If it fails you are out a buck, who hasn't lost a buck or more on a stock? With all the good informative info out there on "Amyloid beta oligomers" and Sabirnetug, it is hard to believe it would fail, so when the P2 trial is finish and reported, whew it's anyone's guess on how high it will go....but I do like Students enthusiastic guess of 200+ per share.......

Student, I am interested in investing here,but worry about why the stock has been soft.

I think they actively stopped recruiting in the United States at the end of December and probably finished worldwide enrollment in the first part of March,

I think those are the approximate dates to use when determining when we should see top line results.

Obviously, there are some patients that have now been treated for 12 months already.

Yes that is the date of the PR, but it doesn't specifically state March 26th as the completion date. Do you really think that was the exact day they completed enrollment?

The clinical trial show they stopped recruiting in Dec 2024......Suggesting they had enough potential patients, and just need to screen out the excess.....So trial was running with enough recruits, and they settled with a group of approximately 540 patients, in Jan, Feb, or Mar.....IMO.....

"Record Verification 2024-11,: Overall Status:Recruiting..

"Record Verification 2024-12 Overall Status : Active, NOT recruiting

Enrollment in Acumen's trial was completed om March 26th of this year.

https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-completes-enrollment-altitude-ad-phase-2

Agree, but still perplexed on why it dropped so much, but took serious advantage of others failure. Accumulated a pile of stocks.

Think you meant, "patients started being treated in June 24." It was filled by late 24 to early 25, which makes me suspect it will end before the estimated date of Oct 2026. Unfortunately management noted there will not be any update on the trial until the end, but being a "Fast Track' drug they will need to send the FDA a mid-trial update. Suspect there will be some leaking, which will be seen in a pop in SP.

Here is a little confusion...The official Clinical Trial site shows Last update on 2024-12-19, but the site below shows there was an update on March 25, 2025. Keep looking on the gov site for update but nothing yet, and can not find what was updated on the Bolderscience site.

https://clinicaltrials.gov/study/NCT06335173?term=ACU-193&rank=3

https://www.bolderscience.com/trial/nct06335173/

Enjoy the climb back up, way-up......

My optimism for this drug could not be higher. It is such an unmet medical need and the potential market couldn't be bigger. This could be the game changer in the treatment of Alzheimers Disease! There is a desperate need!!

When this stock gets recommended by one of Wall Streets respected biotech analysts it will be off to the races. With only 61 million shares outstanding and approximately $3/share in cash (enough cash into 2027 without having to raise funds for the trial) this Company is in the perfect position.

Patients started being treated in this trial in June, 2025 and was fully enrolled early this year with 542 patients. An old Wall Street friend used to say, "Your patience will be rewarded".

Wish everything on the web was date stamped.........but you are correct it is an oldie....best guess would be in late 2023, or early 2024.....but it was a goodie.....The other articles are within a month or two old.....Many articles out there clearly shows Acumen is on the right track tackling amyloid beta oligomers ABOS...........Future is looking up.....

Rafter; What is the date of publication of the Acumen ad in Nature?

Some additional recent articles, which appear to be sparking interesting in Acumen....

1) Acumen Ad...."A new horizon in Alzheimer’s disease: targeting highly neurotoxic amyloid-ß oligomers (AßOs)"

https://www.nature.com/articles/d43747-023-00119-8

2) "New clues as to why drugs are effective for Alzheimer's disease"

"A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the drugs bind to toxic amyloid beta protein to tackle the disease.”

https://medicalxpress.com/news/2025-04-clues-drugs-effective-alzheimer-disease.html

3) "Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease"

https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/trc2.70069

Enjoy the read......and enjoy the ride back up......

Yes, just one of the many good news that has been popping up lately related to Acumen. The May 19, FDA news list the company and names the method....

"Fujirebio, a Japanese diagnostics company, has given physicians a new testing option by securing 510(k) clearance for its Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. The FDA cleared the test for the early detection of amyloid plaques associated with Alzheimer’s in people aged 55 years and older with signs and symptoms of the disease."

https://www.biopharmadive.com/news/fda-blood-test-alzheimers-fujirebio/748473/

Acumen has worked with them for years to develop the method....As can be seen in this Power Point presentation in Nov 2022.

""Critical evaluation and comparison of biomarker values in commercial CSF with Lumipulse® to support assay development for clinical trials"

1st FDA approved blood test for Alzheimer's disease will exponentially increase those people diagnosed with the disease. This test combined with a drug that treats the disease changes the scope of the market opportunity dramatically.

https://news.sky.com/story/blood-test-for-alzheimers-disease-is-highly-accurate-researchers-say-13380314

"Acumen Pharmaceuticals: Balancing Clinical Breakthroughs Against Financial Crossroads – A High-Stakes Alzheimer’s Play"

Nice summary, hit on many of the good and bad issues with ABOS. As we know it's a risk, but the potential is enormous. At the current price, any investors should take the chances, buy some shares, and store them aware. Could lose it all, but at this price and not be a big loss, IMO, but if (when) it is proven, happy days ahead.

https://www.ainvest.com/news/acumen-pharmaceuticals-balancing-clinical-breakthroughs-financial-crossroads-high-stakes-alzheimer-play-2505/

VERY comprehensive presentation from yesterday.....

https://investors.acumenpharm.com/static-files/b27addb9-6f6b-41f8-8d54-554818973383

BTW; Company still has at the end of Q1 $297M cash!!!!

ABOS, new 52 week low

Guess post wasn't specific enough.....They are following the same path as in both are mAb, going after amyloid-beta-oligomers.

Here is the latest list of current and upcoming ALZs drugs, a summary from the APPD conference....as you noted, there are quit a few.........

https://www.delveinsight.com/blog/ad-pd-2025-conference-highlights

Looks to be the start of another market down day, and ABOS follows. How low will it go. Relentlessly beating the heck out of the poor stock, but with the current turmoil going on in the FDA, and other agency, who knows if anything will get thru the regulatory process to market, in a timely fashion....Perplexing times......

There are a lot of people that have had margin calls in this ugly market resulting from other positions. As Acumen is not a marginal security it provides 100% cash release on a sale.

IMO; this is an amazing opportunity to buy shares that are just being thrown away. I'm repeating myself, but Acumen has over $3/share in CASH, doesn't need money to complete this Phase II trial for probably the biggest and most needed disease on this planet!!

If you've read all the information on their website, and listened to all their presentations and read the 10K, you would understand what the value of this Company really is.

Patience is a virtue. This Company can literally go from this current ridiculous price to $200/share over the next 2 years. I can't find a better investment!!!

GLTA!!

ABOS, new 52 week low

Promis is on a different path and has just recently started a Phase I clinical trial and are (IMO) at least 2-3 years behind Acumen in the clinic. Acumen has powerful Phase I results and was FDA cleared to commence a Phase II trial which started enrolling in May 2024 that is now FULLY enrolled!!

Promis is also not well funded and is having difficulty raising equity.

BTW; I hope there are multiple drugs that could help this horrible disease!!

GLTA!!!

Appears to be on the same path.........

"Exploring a vaccine-based approach to targeting Aß oligomers in Alzheimer’s disease"

Noi perplexing.... This latest selling has nothing to do about Acumen. It has to do with someone yesterday had a margin call and needed money. As ABOS is not marginal it provides 100% cash to the desperate seller. This provides a special "opportunity" to a buyer; unfortunate for the seller, I'm sure that's what happened.

Be confident; this Company is advancing great science to help the Alzheimer's population which is a gigantic market and ABOS has the funding in place to complete this Phase II trial.

GLTA!!

Yes can actually say, "Been there, done that," so much good info out there, yet...............Looks like stock got punished today for escaping the downward spiral yesterday, by going up a few pennies. Well took those pennies back and more today.....Go figure.....perplexing it is........

Excellent information.

I also suggest reading the first 15 pages of Acumens 10K filing. Great information there too.

All of Acumen's JPAD 2025, and ADPD 2025 Posters and articles, have been posted on their publication website page. The details and range of the info on Sabirnetug is incredible. Well worth skimming thru them all, even if the science is initially overwhelming, it starts making sense. This company is more then a one drug company, they are an Alzheimer research machine. So please stop selling, it is just to perplexing....👍️..

https://acumenpharm.com/document-library/

Like all of biotech.

However, not all of biotech has completed enrollment is a phase II trial of a VERY impressive Alzheimers drug and also has funding to complete the trial without the need for additional monies.

This is a prime example of the baby being thrown out with the bath water. I was a buyer yesterday!!

ABOS, new 52 week low

Acumen issues press release....

https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-showcases-ptau217-trial-screening

Very upbeat Y/E CC this morning.

At Y/E Acumen had $231M cash and equivalents or over $3.50/per share in cash. Certainly more than enough money to complete the Phase II trial!!

Pura Vida!!

"Can we hope for more then a penny rise on the news........" ......Guess not......😟

Some mighty fine words...."statistically significant amyloid plaque reduction compared to placebo at higher dose multiple-ascending dose cohorts evaluated in the study"

Should be an interesting Annual CC tomorrow.......

The Phase 1 INTERCEPT-AD clinical trial demonstrated sabirnetug was generally well-tolerated with low overall rates of ARIA-E. The trial also showed dose- and exposure-dependent target engagement and statistically significant amyloid plaque reduction compared to placebo at higher dose multiple-ascending dose cohorts evaluated in the study.

These results were after only 3 months of being treated with Sabirnetug in a phase I trial. One might expect significantly greater results in a 18 month trial!! This is a next generation drug!!

Good luck to all the patients!!

Months AHEAD of schedule!!!!

Every milestone has been hit on or ahead of schedule!!

GLTA!!

"Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease"

March 26, 2025 at 8:01 AM EDT

"We look forward to sharing topline results in late 2026 and advancing sabirnetug as a next-generation treatment for Alzheimer’s disease.""

Can we hope for more then a penny rise on the news........

https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-completes-enrollment-altitude-ad-phase-2

There are 500,000 newly diagnosed Alzheimers patients in the US each year. That number is growing due to the aging of our population and new diagnostic blood tests which are expected to increase the actual numbers significantly.

The market is enormous and the 2 FDA approved drugs are being shunned as their side effects create a significant health risk.

Siburnitug showed a MUCH improved safety profile and showed efficacy in a 3 month Phase I trial. My expectations for the current Phase II trial are VERY high!!

If this drug shows what I'm hoping for in the Phase II trial; I can assure you BIG PHARMA will be all over this Company.

GLTA!!

Yes, that has been posted since, "Last Update Posted 2024-12-1." ....made note of it earlier.....been waiting for a comment from Acumen.....Maybe during the Q4 cc.....who knows....See no reason why they could not have posted the SC vs IV news two days earlier so Dan could have discussed it......

This doesn't help........

https://abcnews.go.com/Technology/wireStory/researchers-find-hint-delay-alzheimers-symptoms-now-prove-119968700

Minusha....at current rate stock will soon be de-listed.......Someone needs to explain how this low price is possible? Who is selling all those cheap shares?......

A look a ClinicalTrials.gov now shows that Sabirnetug is an active trial and NOT recruiting patients. IMO; this could only mean that the trial is now FULLY ENROLLED!!

https://clinicaltrials.gov/study/NCT06335173?term=NCT06335173&viewType=Table&rank=1

I would expect a Company announcement to this effect in the very near future!!

Hitting every milestone on or before expectation!!

GLTA!!!

Forget the minusha, and look at the big picture. Acumen is meeting all its milestones on time. They have more than enough cash to finish this Phase II trial. If these results turn out to be what we all are hoping for, Acumen will be bought out by big Pharma for $200+/share.

I have never seen in all my years on/around Wall Street a better Rick vs Reward scenario than this.

Two MAJOR industry presentations coming up and VERY soon an announcement of full enrollment in the Phase II trial.

Could not be looking better. Take advantage of this SALE on shares!!!

GLTA!!

Losing enthusiasm after today's disappointing close......Guess the only person more disappointed would be Dr O'Connell, three presentations in two days, a great PR, and what does he get for it.........a penny.......☹️.......It makes one give up investing in stocks.......

Ticking off each milestone on or before scheduled date.

Next up: Full Enrollment Phase II trial!!

Great.....its a start......I liked this....knew O.Connell was holding back info.....

"We are pleased that the results of our initial clinical study support further clinical development of sabirnetug administered subcutaneously, underscoring the potential for increasing patient convenience of this formulation relative to intravenous treatment,” said Daniel O’Connell, Chief Executive Officer of Acumen. “The timely completion of this study highlights the strength of our clinical team and partners, and our commitment to advancing our clinical pipeline efficiently and effectively. Based on these data, we believe that further development of subcutaneous sabirnetug as a more convenient administration option for patients is warranted.”"

Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-announces-topline-results-phase-1-study

GLTA!!

Well, will need to agree with you again, another nice discussion......best thing, at most, in 9 working days the IV-SC report will be posted....then hopefully the perplexing low SP will come to an end....

Today's Stifel interview was equally interesting and worth watching too. O'Connell exudes EXTREME confident.

I liked to answer to the question on what is the mechanism for Sabirnitug in removing plaque. I think today's interviewer also did an excellent job.

Agree, thought Mr O'Connell did a bang up job, also thought the interviewer did a fine job. Seemed to know Acumen well, and asked some good questions. Liked the discussions on the SC trials. Could tell Dan was holding back, it was obvious he just wanted to say more. Was encouraged when he just had to make note that info on the IV vs Sc trial will be out by the end of Q1 2025…so within two weeks, great. Will bet they present news on the new AI deal when they provide update on the P2 SC trial. Have to also agree, the presentations in early April should be much more interesting after the SC news, and the annual report.

SP should be heading up for a change or will be more perplexed.....

Just listened to Acumen CEO Dan O'Connell have a sit down chat with the UBS analyst. It was an excellent interview and the replay is already available on Acumen's website in the Investor tab.

The CEO mentioned that they have previously stated that the Altitude Phase II trial enrollment would be a first half 2025 event and then went on to say that "enrollment was going quicker and more rapidly than expected". Which translates to me that they are close to full enrollment and I'm looking for an announcement to that effect at one of the big conferences that takes place during the first 2 weeks of April!!

GLTA!!

Going to be an informative couple of weeks with all the up coming presentations, will be listening to all of them. It will be a good change to be perplexed on how high and fast the SP moves back up.......👍️...

Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-present-during-international-conference

Great, would be a good time to present data from the IV/SC trial, an update on the future SC/AI trial, and a mid-term update on the current P2 trial......an investor can hope.......They will also need to post annual report by end of month....so should be getting some new info at some point....Will be listening and looking........

Acumen to Participate in Two Investor Conferences:

https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-participate-upcoming-investor-conferences